Article Text

Download PDFPDF

Original research article
Cost-effectiveness of drug-eluting stents versus bare-metal stents in patients undergoing percutaneous coronary intervention
  1. Louise Baschet1,
  2. Sandrine Bourguignon2,
  3. Sébastien Marque1,
  4. Isabelle Durand-Zaleski3,
  5. Emmanuel Teiger4,
  6. Fanny Wilquin5 and
  7. Karine Levesque5
  1. 1Capionis, Paris, France
  2. 2Stratégique Santé, Paris, France
  3. 3AP-HP Public Health, Henri Mondor Hospital, ECEVE-UMR1123—INSERM & UPEC, Paris, France
  4. 4AP-HP Public Health, Henri Mondor Hospital, Cardiovascular Department and INSERM U955, Creteil, France
  5. 5SNITEM, Courbevoie, France
  1. Correspondence to Louise Baschet; louise.baschet{at}capionis.com

Abstract

Objective To determine the cost-effectiveness of drug-eluting stents (DES) compared with bare-metal stents (BMS) in patients requiring a percutaneous coronary intervention in France, using a recent meta-analysis including second-generation DES.

Methods A cost-effectiveness analysis was performed in the French National Health Insurance setting. Effectiveness settings were taken from a meta-analysis of 117 762 patient-years with 76 randomised trials. The main effectiveness criterion was major cardiac event-free survival. Effectiveness and costs were modelled over a 5-year horizon using a three-state Markov model. Incremental cost-effectiveness ratios and a cost-effectiveness acceptability curve were calculated for a range of thresholds for willingness to pay per year without major cardiac event gain. Deterministic and probabilistic sensitivity analyses were performed.

Results Base case results demonstrated that DES are dominant over BMS, with an increase in event-free survival and a cost-reduction of €184, primarily due to a diminution of second revascularisations, and an absence of myocardial infarction and stent thrombosis. These results are robust for uncertainty on one-way deterministic and probabilistic sensitivity analyses. Using a cost-effectiveness threshold of €7000 per major cardiac event-free year gained, DES has a >95% probability of being cost-effective versus BMS.

Conclusions Following DES price decrease, new-generation DES development and taking into account recent meta-analyses results, the DES can now be considered cost-effective regardless of selective indication in France, according to European recommendations.

  • CORONARY ARTERY DISEASE
  • economic evaluation
  • drug-eluting stents
  • cost-effectiveness model

This is an Open Access article distributed in accordance with the terms of the Creative Commons Attribution (CC BY 4.0) license, which permits others to distribute, remix, adapt and build upon this work, for commercial use, provided the original work is properly cited. See: http://creativecommons.org/licenses/by/4.0/

View Full Text

Statistics from Altmetric.com

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.